CRO competition intensifies as Chinese biotechs rush for global studies

17 February 2021

beijing_china_large_credit_bobby_mcgill_freeimages

By Wang Fangqing

Recent years have seen a growing number of Chinese biotechs doing their clinical studies outside China, reports The Pharma Letter’s local correspondent Wang Fangqing.

Among them are Junshi Biosciences (HKEX: 1877), whose PD1 antibody Tuoyi (toripalimab) started global studies in 2016 and is currently in various stages for multiple indications; Chi-Med (Nasdaq/AIM: HCM), which is conducting global studies for the MET inhibitor savolitinib, and Adagene, which is recruiting patients in China and the US for Phase I studies for its anti CD137 MAb ADG106, a cancer treatment.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK